Exploring the protective effects of vasoactive intestinal peptides on dry eye disease in SARS-CoV-2 survivors.

IF 1.4 3区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Vision Pub Date : 2024-12-31 eCollection Date: 2024-01-01

Konstantin Y Gushansky, Raimo Tuuminen

{"title":"Exploring the protective effects of vasoactive intestinal peptides on dry eye disease in SARS-CoV-2 survivors.","authors":"Konstantin Y Gushansky, Raimo Tuuminen","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to investigate the association between proton pump inhibitors and dry eye disease (DED) among hospitalized SARS-CoV-2 patients.Methods: We conducted a retrospective cohort study using electronic medical records from patients hospitalized for SARS-CoV-2 between April 2020 and December 2023. Eligible participants were aged over 18 years and hospitalized for SARS-CoV-2 without preexisting DED. Exclusions included ICU admissions, malignancies, recent ocular interventions, or chronic medications known to induce dry eye disease. Logistic regression adjusted for age, gender, and vaccination status evaluated associations between gastrointestinal (GI) medications and the subsequent development of dry eye disease within 6 months following hospital discharge.Results: The age and gender distributions within the cohort were representative of the general SARS-CoV-2 infected population. Among 1165 patients, 167 (14.3%) developed dry eye disease post-hospitalization. Laxative use (lactulose and polyethylene glycol) correlated positively with dry eye disease (OR 1.939, p = 0.016; OR 2.094, p = 0.015, respectively). Metoclopramide treatment showed the strongest association (OR 13.413, p < 0.001), with over 50% incidence in affected patients. Conversely, omeprazole showed an inverse correlation with dry eye disease (OR 0.332, p < 0.001). Polypharmacy increased the odds of DED (odds ration [OR] 1.629, p = 0.015), while age, gender, and vaccination status did not significantly influence the outcomes.Conclusions: Our findings emphasize significant correlations between GI medications and dry eye disease in SARS-CoV-2 survivors. Proton pump inhibitors may mitigate the risk of dry eye disease, contrasting with adverse effects linked to laxatives and metoclopramide. Vasoactive intestinal peptide (VIP), which links gut and lacrimal gland functions, is a strong candidate for the basis of the underlying pathophysiological mechanisms.","PeriodicalId":18866,"journal":{"name":"Molecular Vision","volume":"30 ","pages":"489-496"},"PeriodicalIF":1.4000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829782/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Vision","FirstCategoryId":"3","ListUrlMain":"","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to investigate the association between proton pump inhibitors and dry eye disease (DED) among hospitalized SARS-CoV-2 patients.

Methods: We conducted a retrospective cohort study using electronic medical records from patients hospitalized for SARS-CoV-2 between April 2020 and December 2023. Eligible participants were aged over 18 years and hospitalized for SARS-CoV-2 without preexisting DED. Exclusions included ICU admissions, malignancies, recent ocular interventions, or chronic medications known to induce dry eye disease. Logistic regression adjusted for age, gender, and vaccination status evaluated associations between gastrointestinal (GI) medications and the subsequent development of dry eye disease within 6 months following hospital discharge.

Results: The age and gender distributions within the cohort were representative of the general SARS-CoV-2 infected population. Among 1165 patients, 167 (14.3%) developed dry eye disease post-hospitalization. Laxative use (lactulose and polyethylene glycol) correlated positively with dry eye disease (OR 1.939, p = 0.016; OR 2.094, p = 0.015, respectively). Metoclopramide treatment showed the strongest association (OR 13.413, p < 0.001), with over 50% incidence in affected patients. Conversely, omeprazole showed an inverse correlation with dry eye disease (OR 0.332, p < 0.001). Polypharmacy increased the odds of DED (odds ration [OR] 1.629, p = 0.015), while age, gender, and vaccination status did not significantly influence the outcomes.

Conclusions: Our findings emphasize significant correlations between GI medications and dry eye disease in SARS-CoV-2 survivors. Proton pump inhibitors may mitigate the risk of dry eye disease, contrasting with adverse effects linked to laxatives and metoclopramide. Vasoactive intestinal peptide (VIP), which links gut and lacrimal gland functions, is a strong candidate for the basis of the underlying pathophysiological mechanisms.

本刊更多论文

探索血管活性肠肽对SARS-CoV-2幸存者干眼病的保护作用。

目的：探讨质子泵抑制剂与SARS-CoV-2住院患者干眼病（DED）的关系。方法：我们对2020年4月至2023年12月期间因SARS-CoV-2住院的患者的电子病历进行了回顾性队列研究。符合条件的参与者年龄在18岁以上，因SARS-CoV-2住院，先前没有DED。排除包括ICU住院患者、恶性肿瘤、近期眼部干预或已知引起干眼病的慢性药物。经年龄、性别和疫苗接种状况调整后的Logistic回归评估了胃肠道（GI）药物与出院后6个月内干眼病的后续发展之间的关系。结果：队列中的年龄和性别分布代表了一般SARS-CoV-2感染人群。1165例患者中，167例（14.3%）在住院后发生干眼病。使用泻药（乳果糖和聚乙二醇）与干眼病呈正相关(OR 1.939, p = 0.016；OR 2.094, p = 0.015)。甲氧氯普胺治疗的相关性最强（OR 13.413, p < 0.001），患者的发病率超过50%。相反，奥美拉唑与干眼病呈负相关（OR 0.332, p < 0.001）。多药增加了DED的几率（比值比[OR] 1.629, p = 0.015），而年龄、性别和疫苗接种状况对结果无显著影响。结论：我们的研究结果强调了胃肠道药物与SARS-CoV-2幸存者干眼病之间的显著相关性。与泻药和甲氧氯普胺的副作用相比，质子泵抑制剂可减轻干眼症的风险。血管活性肠肽（VIP）连接肠道和泪腺功能，是潜在病理生理机制的有力候选基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Vision 生物-生化与分子生物学

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： Molecular Vision is a peer-reviewed journal dedicated to the dissemination of research results in molecular biology, cell biology, and the genetics of the visual system (ocular and cortical). Molecular Vision publishes articles presenting original research that has not previously been published and comprehensive articles reviewing the current status of a particular field or topic. Submissions to Molecular Vision are subjected to rigorous peer review. Molecular Vision does NOT publish preprints. For authors, Molecular Vision provides a rapid means of communicating important results. Access to Molecular Vision is free and unrestricted, allowing the widest possible audience for your article. Digital publishing allows you to use color images freely (and without fees). Additionally, you may publish animations, sounds, or other supplementary information that clarifies or supports your article. Each of the authors of an article may also list an electronic mail address (which will be updated upon request) to give interested readers easy access to authors.